Attach selected cage option to customer supplied compound bearing suitable reactive chemistry. Minimum goal of 100 μl of 1 mM final caged material. Several proprietary cage options are available that are based on the 2-nitro-benzyl group (Eclipse1.0™), as well as on the 6-bromo-7-hydroxycoumarin-4-ylmethyl (Bhc) group (Eclipse2.0™) that is suitable for one- and two-photon uncaging (U.S. Patent 6,472,541). The proprietary Pulsar1.0™ caging group (patent pending) permits the progress of uncaging to be followed by the evolution of blue fluorescence concurrently with photocleavage.
It cannot be predicted in advance whether a custom chemical synthesis will prove untenable. If this is the case, there will be no charge to the customer. SuperNova Life Science will attempt to employ a variety of proprietary caging chemistries to optimize solubility and other physicochemical properties of the final caged molecule, but these cannot be guaranteed.